189 related articles for article (PubMed ID: 26472316)
41. Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in England.
Khakwani A; Harden S; Beckett P; Baldwin D; Navani N; West D; Hubbard R
Thorax; 2020 Mar; 75(3):237-243. PubMed ID: 31879316
[TBL] [Abstract][Full Text] [Related]
42. Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review.
Chen H; Laba JM; Zayed S; Boldt RG; Palma DA; Louie AV
J Thorac Oncol; 2019 Aug; 14(8):1332-1342. PubMed ID: 31075543
[TBL] [Abstract][Full Text] [Related]
43. The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.
Shaverdian N; Tenn S; Veruttipong D; Wang J; Hegde J; Lee C; Cao M; Agazaryan N; Steinberg M; Kupelian P; Lee P
Br J Radiol; 2016; 89(1059):20150963. PubMed ID: 26764282
[TBL] [Abstract][Full Text] [Related]
44. Long-term outcomes in patients with central and ultracentral non-small cell lung cancer treated with stereotactic body radiotherapy: single-institution experience.
Song X; Zhao L; Jiang N; Ding N; Zong D; Zhang N; Wang D; Wen J; He X; Kong C; Zhu X
Curr Probl Cancer; 2023 Jun; 47(3):100956. PubMed ID: 36966677
[TBL] [Abstract][Full Text] [Related]
45. Stereotactic ablative radiation therapy for subcentimeter lung tumors: clinical, dosimetric, and image guidance considerations.
Louie AV; Senan S; Dahele M; Slotman BJ; Verbakel WF
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):843-9. PubMed ID: 25585783
[TBL] [Abstract][Full Text] [Related]
46. Correlation of dose computed using different algorithms with local control following stereotactic ablative radiotherapy (SABR)-based treatment of non-small-cell lung cancer.
Chetty IJ; Devpura S; Liu D; Chen D; Li H; Wen NW; Kumar S; Fraser C; Siddiqui MS; Ajlouni M; Movsas B
Radiother Oncol; 2013 Dec; 109(3):498-504. PubMed ID: 24231237
[TBL] [Abstract][Full Text] [Related]
47. Sinoatrial node toxicity after stereotactic ablative radiation therapy to lung tumors.
Qian Y; Zhu H; Pollom EL; Durkee BY; Chaudhuri AA; Gensheimer MF; Diehn M; Shultz DB; Loo BW
Pract Radiat Oncol; 2017; 7(6):e525-e529. PubMed ID: 28669706
[TBL] [Abstract][Full Text] [Related]
48. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
Eufemon Cereno R; Mou B; Baker S; Chng N; Arbour G; Bergman A; Liu M; Schellenberg D; Matthews Q; Huang V; Mestrovic A; Hyde D; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Jiang W; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson RA
Radiother Oncol; 2023 May; 182():109576. PubMed ID: 36822355
[TBL] [Abstract][Full Text] [Related]
49. SABR vs. Limited Resection for Non-small Cell Lung Cancer: Are We Closer to an Answer?
Chen H; Louie AV
Curr Treat Options Oncol; 2016 Jun; 17(6):27. PubMed ID: 27098533
[TBL] [Abstract][Full Text] [Related]
50. Variation in Lung Tumour Breathing Motion between Planning Four-dimensional Computed Tomography and Stereotactic Ablative Radiotherapy Delivery and its Dosimetric Implications: Any Role for Four-dimensional Set-up Verification?
Ruben JD; Seeley A; Panettieri V; Ackerly T
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):21-7. PubMed ID: 26432188
[TBL] [Abstract][Full Text] [Related]
51. Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned.
Chang JY; Bezjak A; Mornex F;
J Thorac Oncol; 2015 Apr; 10(4):577-85. PubMed ID: 25514807
[TBL] [Abstract][Full Text] [Related]
52. MLC tracking for lung SABR reduces planning target volumes and dose to organs at risk.
Caillet V; Keall PJ; Colvill E; Hardcastle N; O'Brien R; Szymura K; Booth JT
Radiother Oncol; 2017 Jul; 124(1):18-24. PubMed ID: 28655454
[TBL] [Abstract][Full Text] [Related]
53. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity.
Goldsmith C; Plowman PN; Green MM; Dale RG; Price PM
Radiat Oncol; 2018 Oct; 13(1):204. PubMed ID: 30340643
[TBL] [Abstract][Full Text] [Related]
54. Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors: New insights and approaches.
Tekatli H; Spoelstra FOB; Palacios M; van Sornsen de Koste J; Slotman BJ; Senan S
Lung Cancer; 2018 Sep; 123():142-148. PubMed ID: 30089586
[TBL] [Abstract][Full Text] [Related]
55. Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer.
Iyengar P; Westover K; Timmerman RD
Semin Respir Crit Care Med; 2013 Dec; 34(6):845-54. PubMed ID: 24258574
[TBL] [Abstract][Full Text] [Related]
56. Stereotactic radiotherapy of intrapulmonary lesions: comparison of different dose calculation algorithms for Oncentra MasterPlan®.
Troeller A; Garny S; Pachmann S; Kantz S; Gerum S; Manapov F; Ganswindt U; Belka C; Söhn M
Radiat Oncol; 2015 Feb; 10():51. PubMed ID: 25888786
[TBL] [Abstract][Full Text] [Related]
57. Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis.
Mokhles S; Verstegen N; Maat AP; Birim Ö; Bogers AJ; Mokhles MM; Lagerwaard FJ; Senan S; Takkenberg JJ
Lung Cancer; 2015 Mar; 87(3):283-9. PubMed ID: 25622781
[TBL] [Abstract][Full Text] [Related]
58. Virtual Bronchoscopy-Guided Treatment Planning to Map and Mitigate Radiation-Induced Airway Injury in Lung SAbR.
Kazemzadeh N; Modiri A; Samanta S; Yan Y; Bland R; Rozario T; Wibowo H; Iyengar P; Ahn C; Timmerman R; Sawant A
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):210-218. PubMed ID: 29891202
[TBL] [Abstract][Full Text] [Related]
59. A dosimetric parameter to limit chest wall toxicity in SABR of NSCLC.
Jumeau R; Filion É; Bahig H; Vu T; Lambert L; Roberge D; Doucet R; Campeau MP
Br J Radiol; 2017 Jul; 90(1075):20170196. PubMed ID: 28590814
[TBL] [Abstract][Full Text] [Related]
60. Comparison of Single-fraction and Multi-fraction Stereotactic Radiotherapy for Patients with 18F-fluorodeoxyglucose Positron Emission Tomography-staged Pulmonary Oligometastases.
Siva S; Kirby K; Caine H; Pham D; Kron T; Te Marvelde L; Whalley D; Stevens MJ; Foroudi F; MacManus M; Ball D; Eade T
Clin Oncol (R Coll Radiol); 2015 Jun; 27(6):353-61. PubMed ID: 25698068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
